Cohesion Corp. receives IDE approval and begins clinical trials with CollaSeal Hemostatic Device.PALO ALTO, Calif.--(BW HealthWire)--April 9, 1997--Cohesion Corp. (a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. ) today announced the beginning of clinical trials using its CollaSeal(TM) Hemostatic Device in the control of bleeding during surgery. Previously, Cohesion Corp. received Investigational Device Exemption An Investigational Device Exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval (PMA) application or a Premarket Notification [510(k)] submission to Food and (IDE) approval by the Food and Drug Administration (FDA). These studies of this bioresorbable atraumatic atraumatic /atrau·mat·ic/ (a?traw-mat´ik) not producing injury or damage. atraumatic not producing injury or damage. atraumatic adjective Without injury hemostatic device, commenced at University of Southern California The U.S. News & World Report ranked USC 27th among all universities in the United States in its 2008 ranking of "America's Best Colleges", also designating it as one of the "most selective universities" for admitting 8,634 of the almost 34,000 who applied for freshman admission (USC) Medical Center and Santa Clara Valley
The Santa Clara Valley is a valley just south of the San Francisco Bay in Northern California in the United States. Medical Center. Additional clinical studies are scheduled to be conducted in Europe and the United States later this year. Cohesion Corp. is engaged in the business of discovery, development and commercialization of bioresorbable materials for guided tissue repair and regeneration. Proprietary technologies in the fields of collagen/fibrin tissue adhesives and hydrophilic polymers for in situ polymerization provide Cohesion with cutting edge opportunities in the fields of tissue adhesives, tissue sealants, and barriers to prevent post-surgical adhesions. CONTACT: Cohesion Corp., Palo Alto Frank DeLustro, 415/856-0200 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion